On July 28, 2026, Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma, purchased 3,363 ordinary shares on NASDAQ at $1.49 per share, increasing his total holdings to 20,030 shares. OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.

OKYO Pharma Ltd announced its participation in the virtual BTIG Biotechnology Conference 2026 scheduled for July 28-29, 2026. Management representatives attending include CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli. The company plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP). OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.

Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on NASDAQ at $1.48 per share, increasing his total holding to 35,201 shares. OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.

On July 23, 2026, CEO Robert J. Dempsey purchased 15,000 ordinary shares of OKYO Pharma on the NASDAQ at a price of $1.54 per share. The company is a clinical-stage biopharmaceutical firm developing therapies for neuropathic corneal pain and anterior segment eye diseases.

Chairman Gabriele Cerrone, through Panetta Partners Ltd, purchased 22,500 ordinary shares at $1.45 per share, increasing his total holding to 10,873,916 shares, representing 20.55% of issued share capital. OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.